Philip Greenberg

Q: What Schools Are Affiliated With Philip Greenberg

Philip Greenberg is affiliated with the following schools: University of California, San Diego, Stanford University, Juntendo University, University of Washington

Philip Greenberg's AcademicInfluence.com Rankings

Philip Greenberg

Engineering

#3202

World Rank

#4241

Historical Rank

Biomedical Engineering

#129

World Rank

#131

Historical Rank

Applied Physics

#544

World Rank

#563

Historical Rank

engineering Degrees

Philip Greenberg

Biology

#4337

World Rank

#6480

Historical Rank

Immunology

#181

World Rank

#189

Historical Rank

biology Degrees

Download Badge

Engineering
Biology

Why Is Philip Greenberg Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. He is a co-founder of Juno Therapeutics.

(See a Problem?)

Philip Greenberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. (1995) (1910)
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells (2002) (1258)
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. (1992) (1255)
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients (1999) (1216)
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. (2006) (808)
Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. (1991) (678)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. (2008) (673)
Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. (1991) (664)
Cancer Immunotherapy: A Treatment for the Masses (2004) (610)
T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients (1996) (579)
Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. (1994) (507)
Tolerance and exhaustion: defining mechanisms of T cell dysfunction. (2014) (490)
Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. (1999) (462)
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. (2012) (460)
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer (2012) (424)
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. (2016) (420)
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. (2017) (416)
Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus‐specific cytotoxic T lymphocytes (1994) (381)
Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. (2007) (376)
The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. (1990) (369)
Facilitating matched pairing and expression of TCR chains introduced into human T cells. (2007) (365)
Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. (2004) (363)
In vivo migration and function of transferred HIV-1-specific cytotoxic T cells (1999) (361)
Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19 (2020) (351)
Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes (1981) (336)
Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma (2000) (335)
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein (1991) (335)
Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells (1985) (314)
Multiple early factors anticipate post-acute COVID-19 sequelae (2022) (313)
Cytomegalovirus selectively blocks antigen processing and presentation of its immediate–early gene product (1996) (308)
Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation (1994) (289)
The IL-2 Receptor Promotes Lymphocyte Proliferation and Induction of the c-myc, bcl-2, and bcl-x Genes Through the trans-Activation Domain of Stat51 (2000) (279)
Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients (2013) (274)
Principles for adoptive T cell therapy of human viral diseases. (1995) (270)
Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2 (1982) (268)
Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity (2014) (264)
Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5 (2004) (255)
Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors (2006) (248)
Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. (1998) (240)
Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. (1991) (227)
CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. (1999) (215)
Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane1 (2008) (203)
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. (2007) (202)
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. (1993) (195)
The Human UTY Gene Encodes a Novel HLA-B8-Restricted H-Y Antigen1 (2000) (187)
Transfer of Specificity for Human Immunodeficiency Virus Type 1 into Primary Human T Lymphocytes by Introduction of T-Cell Receptor Genes (2000) (184)
Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. (1993) (179)
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant (2019) (176)
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA (2018) (169)
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. (1984) (169)
Safety of retroviral gene marking with a truncated NGF receptor (2003) (168)
Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State (2012) (167)
TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes (2015) (163)
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens (2012) (162)
Shaping of Human Germline IgH Repertoires Revealed by Deep Sequencing (2012) (162)
Restoration of CD28 Expression in CD28− CD8+ Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production (2003) (160)
T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. (2015) (153)
Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain (2009) (152)
Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. (2003) (151)
Prospects for adoptive T cell therapy. (1997) (149)
Bone marrow transplantation in patients aged 45 years and older. (1986) (148)
In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire. (2006) (146)
CD27 Expression Promotes Long-Term Survival of Functional Effector–Memory CD8+Cytotoxic T Lymphocytes in HIV-infected Patients (2004) (146)
Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. (1982) (138)
CD 20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD 28 and 4-1 BB domains : pilot clinical trial results (2012) (136)
Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2. (1981) (136)
T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma (2017) (135)
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. (1980) (125)
Single-cell analysis of normal and FOXP 3-mutant human T cells : FOXP 3 expression without regulatory T cell development (2006) (125)
Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+ and CD8+ T Cells1 (2001) (123)
Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. (1997) (121)
Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death (2002) (120)
Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus (1993) (119)
CD8+ T Cell Tolerance to a Tumor-associated Antigen Is Maintained at the Level of Expansion Rather than Effector Function (2002) (116)
Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. (1998) (116)
Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. (1986) (109)
The IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell viability through the adapter molecule Shc. (1998) (108)
Deficient cellular immunity--finding and fixing the defects. (1999) (108)
Stromal reengineering to treat pancreas cancer. (2014) (107)
Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. (1982) (107)
Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. (1996) (106)
T cell therapy of human CMV and EBV infection in immunocompromised hosts (1997) (106)
Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia. (1986) (103)
Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. (2002) (102)
Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo. (1984) (101)
Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells (2014) (100)
Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long- term as functional memory T cells (1986) (99)
Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity. (2011) (99)
Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains (2018) (98)
Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge (2003) (97)
T cell receptor gene therapy for cancer. (2009) (96)
Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. (1986) (94)
HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. (2000) (93)
CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. (1991) (93)
Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. (1994) (92)
Bone marrow transplantation for refractory acute leukemia in 34 patients with identical twins. (1981) (90)
Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. (2004) (90)
The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. (1990) (88)
An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues (1993) (87)
Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth. (1985) (87)
Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. (1998) (87)
A Public Database of Memory and Naive B-Cell Receptor Sequences (2016) (85)
Treatment of aplastic anemia by bone marrow transplantation in identical twins. (1980) (84)
Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice. (2010) (84)
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. (2016) (84)
Retinoic Acid as a Vaccine Adjuvant Enhances CD8+ T Cell Response and Mucosal Protection from Viral Challenge (2011) (84)
Re‐adapting T cells for cancer therapy: from mouse models to clinical trials (2014) (83)
Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. (1993) (82)
FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens (1989) (80)
Inflammatory monocytes hinder antiviral B cell responses (2016) (80)
Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins. (1981) (79)
Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified CD8+ HIV-Specific T Cells for HIV Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant. Fred Hutchinson Cancer Research Center and the University of Washington (1992) (79)
Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells (2020) (77)
Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen1 (2001) (77)
Interferon-driven deletion of antiviral B cells at the onset of chronic infection (2016) (76)
The IL-4 receptor alpha-chain cytoplasmic domain is sufficient for activation of JAK-1 and STAT6 and the induction of IL-4-specific gene expression. (1997) (75)
Multiple Innate Immune Pathways Contribute to the Immunogenicity of Recombinant Adenovirus Vaccine Vectors (2010) (75)
A membrane-proximal region of the interleukin-2 receptor gamma c chain sufficient for Jak kinase activation and induction of proliferation in T cells (1996) (74)
Identical-twin (syngeneic) marrow transplantation for hematologic cancers. (1986) (74)
Development of a Treatment Regimen for Human Cytomegalovirus (CMV) Infection in Bone Marrow Transplantation Recipients by Adoptive Transfer of Donor‐Derived CMV‐Specific T Cell Clones Expanded In Vitro a (1991) (74)
Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses (2002) (72)
Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells. (1984) (71)
Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients. (1991) (71)
T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. (1991) (70)
T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. (2000) (69)
Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909 (2010) (68)
Treatment of hairy-cell leukemia with chemoradiotherapy and identical-twin bone-marrow transplantation. (1982) (65)
Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient (2016) (65)
Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. (2013) (63)
Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities (2008) (63)
Nonmyeloablative Immunosuppressive Regimen Prolongs In Vivo Persistence of Gene-Modified Autologous T Cells in a Nonhuman Primate Model (2001) (63)
MicroRNA-150 regulates the cytotoxicity of natural killers by targeting perforin-1. (2014) (63)
Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. (2004) (62)
Protection from pathogenic SIV challenge using multigenic DNA vaccines. (1999) (62)
In vivo tracking of tumor-specific T cells. (2001) (62)
Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. (2011) (61)
Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. (1994) (61)
Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments. (2009) (59)
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. (2012) (58)
Potential for specific cancer therapy with immune T lymphocytes. (1984) (57)
The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets. (1999) (57)
Gab3-Deficient Mice Exhibit Normal Development and Hematopoiesis and Are Immunocompetent (2003) (57)
Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. (2009) (56)
IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes. (1988) (55)
Abrogation of Src Homology Region 2 Domain-Containing Phosphatase 1 in Tumor-Specific T Cells Improves Efficacy of Adoptive Immunotherapy by Enhancing the Effector Function and Accumulation of Short-Lived Effector T Cells In Vivo (2012) (55)
Induction of Potent Human Immunodeficiency Virus Type 1-Specific T-Cell-Restricted Immunity by Genetically Modified Dendritic Cells (2001) (55)
Requirement for an initial signal from the membrane-proximal region of the interleukin 2 receptor gamma(c) chain for Janus kinase activation leading to T cell proliferation. (1997) (54)
Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19 (2021) (53)
Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia. (1980) (53)
Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. (2008) (53)
Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains (2011) (51)
Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. (1994) (49)
Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. (1996) (49)
Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR. (2009) (49)
Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory. (1987) (49)
Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10 (2013) (48)
Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones. (1994) (47)
T-cell immunotherapy: looking forward. (2014) (47)
SHP-1 in T Cells Limits the Production of CD8 Effector Cells without Impacting the Formation of Long-Lived Central Memory Cells (2010) (46)
Suppressor of Cytokine Signaling 2 Regulates IL-15–Primed Human NK Cell Function via Control of Phosphorylated Pyk2 (2010) (45)
Tracking the fate and origin of clinically relevant adoptively transferred CD8+ T cells in vivo (2017) (45)
CD8+ cytotoxic T cell therapy of cytomegalovirus and HIV infection. (1993) (43)
Development of a novel strategy for engineering high-affinity proteins by yeast display. (2006) (43)
Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. (2013) (43)
Molecular Pathways: Myeloid Complicity in Cancer (2014) (43)
Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy (2011) (43)
HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. (2011) (42)
Selective Delivery of Augmented IL-2 Receptor Signals to Responding CD8+ T Cells Increases the Size of the Acute Antiviral Response and of the Resulting Memory T Cell Pool1 (2002) (41)
CD8+ T cell responses: it's all downhill after their prime ... (2002) (41)
Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: II. Comparison of cells cultured with and without tumor to noncultured immune cells. (1978) (40)
Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure. (1997) (40)
A minimally replicative HIV-2 live-virus vaccine protects M. nemestrina from disease after HIV-2(287) challenge. (1998) (40)
RasGRP1 Is Required for Human NK Cell Function1 (2009) (39)
Helper-independent CD8+ cytotoxic T lymphocytes express IL-1 receptors and require IL-1 for secretion of IL-2. (1989) (39)
Therapy of disseminated tumors by adoptive transfer of specifically immune T cells. (1988) (39)
Enhanced transgene expression in quiescent and activated human CD8+ T cells. (2004) (39)
Expression of Herpes Simplex Virus ICP47 and Human Cytomegalovirus US11 Prevents Recognition of Transgene Products by CD8+ Cytotoxic T Lymphocytes (2000) (38)
H-2 restriction of adoptive immunotherapy of advanced tumors. (1981) (37)
Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination (1996) (36)
Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma (2019) (34)
Engineering recombinant reoviruses with tandem repeats and a tetravirus 2A-like element for exogenous polypeptide expression (2013) (33)
PD-1 blockade: rescue from a near-death experience (2006) (33)
Cytotoxic and proliferative T cell responses in HIV-1-infected Macaca nemestrina. (1995) (32)
Mathematical Modeling of Chimeric TCR Triggering Predicts the Magnitude of Target Lysis and Its Impairment by TCR Downmodulation (2010) (31)
A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. (2017) (31)
Polyethyleneimine is a potent mucosal adjuvant for glycoproteins with innate and adaptive immune activating properties (2012) (31)
Adoptive therapy with CD8 + T cells (2002) (31)
miR-150-Mediated Foxo1 Regulation Programs CD8+ T Cell Differentiation. (2017) (31)
New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies (2015) (30)
Generation of TCRs of higher affinity by antigen-driven differentiation of progenitor T cells in vitro (2017) (29)
Cell-Intrinsic Abrogation of TGF-β Signaling Delays but Does Not Prevent Dysfunction of Self/Tumor-Specific CD8 T Cells in a Murine Model of Autochthonous Prostate Cancer (2012) (27)
Induction of Tolerance in CD8+ T Cells to a Transgenic Autoantigen Expressed in the Liver Does Not Require Cross-Presentation1 (2007) (26)
Ontogeny of Recognition Specificity and Functionality for the Broadly Neutralizing Anti-HIV Antibody 4E10 (2014) (26)
Expression of chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-dependent growth. (1999) (25)
Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer (2019) (24)
Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. (2004) (24)
Therapy of leukemia by nonimmune syngeneic spleen cells. (1980) (24)
Potential uses of interleukin 2 in cancer therapy. (1986) (24)
Genetic modification of T-cell clones for therapy of human viral and malignant diseases. (1998) (23)
Cellular adoptive immunotherapy after bone marrow transplantation. (1995) (23)
Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells. (1990) (23)
Hepatitis C Virus Immune Escape via Exploitation of a Hole in the T Cell Repertoire1 (2008) (22)
Shared Antigen-specific CD8+ T cell Responses Against the SARS-COV-2 Spike Protein in HLA A*02:01 COVID-19 Participants (2020) (22)
Adoptive immunotherapy of human cytomegalovirus infection: potential role in protection from disease progression. (1991) (21)
Immunization against SIVmne in macaques using multigenic DNA vaccines (1999) (21)
Sterile inflammation induced by Carbopol elicits robust adaptive immune responses in the absence of pathogen-associated molecular patterns (2016) (21)
DNA fusion gene vaccination mobilizes effective anti‐leukemic cytotoxic T lymphocytes from a tolerized repertoire (2008) (20)
Effector mechanisms operative in adoptive therapy of tumor-bearing animals: implications for the use of interleukin-2. (1984) (19)
Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses. (1994) (19)
Tumor-specific T-cell immunity: ready for prime time? (1992) (19)
A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy (2020) (18)
Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients. (1990) (18)
Viral dynamics of early HIV infection in neonatal macaques after oral exposure to HIV‐2287: an animal model with implications for maternal–neonatal HIV transmission (2002) (17)
Peptide-MHC Tetramers CTL from Heterogeneous Populations Using Isolation of High Avidity Melanoma-Reactive and (1999) (17)
Lyt-2+ cells. Requirements for concanavalin A-induced proliferation and interleukin 2 production. (1987) (17)
Cytotoxic T cells specific for cytomegalovirus : a potential therapy for immunocompromised patients. Discussion (1991) (17)
Cytotoxic T cells specific for cytomegalovirus : a potential therapy for immunocompromised patients. Discussion (1991) (17)
Immunotherapy of human viral and malignant diseases with genetically modified T-cell clones. (2000) (16)
Opposite Effects of Endogenous Peptide–MHC Class I on T Cell Activity in the Presence and Absence of CD8 (2011) (16)
Evaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1 (1994) (16)
Suppression of the in vitro secondary response to syngeneic tumor and of in vivo tumor therapy with immune cells by culture-induced suppressor cells. (1979) (16)
Evaluation of gp160 vaccinees in the hu-PBL-SCID mouse model. (1992) (16)
CpG oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection. (2007) (15)
Chronic Graft-versus-Host Disease: Pathogenesis, Diagnosis, Treatment, and Prognostic Factors (1988) (15)
Effect of interleukin-2 on biodistribution of monoclonal antibody in tumor and normal tissues in mice bearing SL-2 thymoma. (1992) (15)
Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro. (1981) (15)
DNA ploidy of fibrolamellar hepatocellular carcinoma by image analysis. (1994) (15)
T-Cell Immunotherapy: Looking Forward: T Cell Immunotherapy: Optimizing Trial Design Bethesda, Maryland 10-11 September 2013. (2014) (14)
T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma. (2002) (14)
CD 8 1 minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells (1999) (13)
Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab. (2017) (12)
Il-4 is an endogenous T cell growth factor during the immune response to a syngeneic retrovirus-induced tumor. (1988) (12)
In vivo administration of interleukin-2. (1985) (12)
Requirements for T cell recognition and elimination of retrovirally-transformed cells. (1988) (12)
HIV-1 Vpr does not inhibit CTL-mediated apoptosis of HIV-1 infected cells. (2002) (12)
Treatment of multiple myeloma (MM) with chemoradiotherapy and identical twin bone marrow transplantation (BMT) (1982) (11)
Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses. (2005) (11)
Transferred Donor-Derived Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor Can Persist and Provide Anti-Leukemic Activity in AML Patients Post-Transplant (2014) (11)
Therapy of Established Tumors by Adoptive Transfer of T Lymphocytes (1983) (10)
Chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: effect of culture duration on therapeutic efficacy. (1981) (10)
Antigen Sensitivity of CD 22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane 1 (2008) (10)
Helper T cell-independent proliferation of CD8+ cytotoxic T lymphocytes transduced with an IL-1 receptor retrovirus. (1994) (10)
HIV-infected macrophages as efficient stimulator cells for detection of cytotoxic T cell responses to HIV in seronegative and seropositive vaccine recipients. (1994) (10)
MicroRNA-150 modulates intracellular Ca2+ levels in naïve CD8+ T cells by targeting TMEM20 (2017) (9)
Antigen recognition by primed T lymphocytes in vitro. I. Separation of recognitive and proliferative phases of antigen-induced T cell activation. (1978) (9)
Pancreatic Cancer: Planning Ahead for Metastatic Spread. (2016) (9)
Application of T cell immunotherapy for human viral and malignant diseases. (2000) (8)
Effector mechanisms by which adoptively transferred T cells promote tumor eradication. (1987) (8)
Cancer Turning in on death programs (1998) (8)
EBV-Specific Donor Cells Transduced to Express a High-Affinity WT1 TCR Can Prevent Recurrence in Post-HCT Patients with High-Risk AML (2016) (8)
Distinct phenotypic expression of immunogenicity and immunosensitivity in sublines of a tumor. (1981) (7)
Identical twin bone marrow transplantation for hairy cell leukemia. (1984) (7)
Treatment of established tumor by adoptive immunotherapy with specifically immune T cells (1985) (6)
Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting (2013) (6)
Adoptive immunotherapy of metastatic B16 melanoma with allogeneic immune cells sensitized to minor histocompatibility antigens. (1985) (6)
Interleukin-2 administered in vivo induces the growth and augments the function of cultured T cells in vivo. (1984) (6)
Antigen‐specific cytokine responses in vaccinated Macaca nemestrina (1999) (5)
A CD 200 RCD 28 fusion protein appropriates an inhibitory signal to enhance T cell function and therapy of murine leukemia Running title : CD 200 R / CD 28 enhances antileukemia T cell efficacy (2017) (5)
Specific adoptive immunotherapy. (1989) (5)
A Transcriptional Block in the IL-2 Promoter at the −150 AP-1 Site in Effector CD8+ T Cells1 (2001) (5)
Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain V α V β fragments (2009) (4)
Targeting an alternate Wilms’ tumor antigen 1 peptide bypasses immunoproteasome dependency (2022) (4)
Identification of a unique T cell-derived lymphokine that primes macrophages for tumor cytotoxicity. (1989) (4)
Lymphocyte Transfer for Cancer Therapy (1984) (4)
Adoptive immunotherapy of human cytomegalovirus infection (1991) (3)
Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals. (1994) (3)
Specific adoptive immunotherapy: Experimental basis and future potential (1982) (3)
T Cell Immunotherapy: Optimizing Trial Design (2014) (3)
Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy (2021) (3)
Adoptive Immunotherapy With Antigen‐Specific T Cells (2007) (3)
Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease. (2020) (3)
DEFINITION OF ALIEN H‐2 DETERMINANTS ON A FRIEND LEUKAEMIA BY ANALYSIS OF ALLOREACTIVITY OF CTL FROM PRIMARY MLC (1981) (3)
Phase I Trial Results Testing Adoptively Transferred T Cells Expressing CD20-Specific Chimeric Antigen Receptors Containing CD28 and CD137 Costimulatory Domains In Patients with Mantle Cell Lymphoma and Indolent Lymphoma (2010) (2)
Immunopathogenesis of HIV infection. (1992) (2)
Expression of a CD200-targeted chimeric costimulatory receptor enhances T cell effector function and adoptive immunotherapy of disseminated leukemia (2016) (2)
TCR Gene Editing Results in Effective Immunotherapy of Leukemia without the Development of GvHD (2011) (2)
Abstract 2937: Editing central memory T lymphocyte specificity for safe and effective adoptive immunotherapy of leukemia (2010) (2)
Pillars article: Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J. Exp. Med. 1981. 154: 952-963. (2013) (2)
Expanding the scope of WT1- and cyclin A1-specific TCR gene therapy for AML and other cancers (2016) (2)
ADOPTIVE CELLULAR IMMUNOTHERAPY1 (1985) (2)
53. Preliminary Results of a Pilot Phase I Clinical Trial of Adoptive Immunotherapy for B Cell Lymphoma Using CD8+ T Cells Genetically Modified To Express a Chimeric T Cell Receptor Recognizing CD20 (2006) (2)
Antigen-specific cultured T cells can mediate tumor therapy and provide long-term immunologic memory in vivo. (1987) (2)
Genetic modification of T cell clones to improve the safety and efficacy of adoptive T cell therapy. (1994) (2)
Bone Marrow Transplantation or Chemotherapy After Remission Induction for Adults with Acute Nonlymphoblastic Leukemia (2020) (2)
Ralph M. Steinman: A man, a microscope, a cell, and so much more (2011) (2)
Cheating death: a Fas-41BB immunomodulatory fusion protein obviates a death signal to enhance T cell function and adoptive therapy targeting leukemia and solid tumors (2018) (1)
Stem cells and cancer immunotherapy: Arrowhead’s 2nd annual cancer immunotherapy conference (2014) (1)
Generation of lymphokine-activated killer (LAK) activity in vivo with recombinant interleukin 2 (1985) (1)
Therapy of human viral and malignant diseases with gene-modified T cell clones (2000) (1)
DEVELOPMENTS IN THE DIAGNOSIS, PREVENTION AND THERAPY OF VIRAL INFECTIONS AFTER BONE MARROW TRANSPLANTATION : A FOCUS ON ADOPTIVE CELLULAR IMMUNOTHERA PY (1996) (1)
AACR Calls on Congress to Take Immediate Action Against COVID-19 and Protect Patients with Cancer During the Pandemic. (2020) (1)
From TCR Gene Transfer to TCR Gene Editing of Central Memory T Lymphocytes for Immunotherapy of Leukemia. (2009) (1)
it's all downhill after their prime … (2002) (1)
Requirement for early and late anti-tumor responses in immunotherapy of established tumor. Abstr. (1979) (1)
Culture-induced suppression. Relevance to in vitro sensitization and tumor therapy. Abstr. (1978) (1)
Induction of Tolerance in CD 8 T Cells to a Transgenic Autoantigen Expressed in the Liver Does Not Require (2007) (1)
Abstract LB-136: IL-21-derived melanoma-reactive CTL combined with anti-CTLA4 persist, acquire central memory characteristics, and mediate tumor regression in patients with metastatic melanoma (2012) (1)
Abstract IA01: Engineering T cell responses to tumors: Taking the immune system where no responses have gone before (2016) (1)
Abstract A51: High-throughput method identifies rare, high-affinity, thymus-vetted T cell receptors (TCRs) for clinical translation (2018) (1)
Bone Marrow Transplantation for Neoplasia in Man (1984) (1)
Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer (2022) (1)
Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19 (2021) (1)
Alloantiserum-mediated supperssion of Ir gene controlled antigen-induced lymphocyte activation: effect on uridine and leucine incorporation. (1975) (1)
Correction: Shaping of Human Germline IgH Repertoires Revealed by Deep Sequencing (2014) (1)
Cbl-b-deficiency in tumor-reactive CD8+ T cells improves efficacy and bypasses the requirement for IL-2 administration during adoptive therapy of progressive leukemia (40.38) (2009) (0)
Response from Gilbert, Riddell and Greenberg (1997) (0)
Large libraries of single-chain trimer peptide-MHCs enable rapid antigen-specific CD8+ T cell discovery and analysis (2022) (0)
cell cytotoxicity Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK (2012) (0)
Engineering T cell receptors for potential therapeutic applications (48.28) (2007) (0)
Immunobiology of rheumatoid arthritis. (1976) (0)
Abstract IA17: Utilizing synthetic biology and high-dimensional probing to address therapeutic obstacles and empower engineered T cells with the capacity to eradicate tumors (2019) (0)
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA (2018) (0)
Loss of pre-existing tumor-specific T-cells and increase in regulatory T-cells after peptide-vaccination in combination with PADRE, CpG 7909, and Montanide ISA51 (41.42) (2009) (0)
Mechanism of T cell mediated hemorrhagic disease during LCMV infection (2020) (0)
Single cell RNA sequencing reveals AML immunoediting under pressure from engineered T cell therapy (2018) (0)
Requirements for the generation of a Lyt-2+ T-cell proliferative response to a syngeneic tumor in the absence of L3T4+ T-cells. (1990) (0)
Abstract I11: Targeting pancreatic cancer with TCR-engineered T cells (2019) (0)
Identification of a macrophage activation factor (MAF) distinct from gamma interferon (. gamma. IF) which induces macrophage cytotoxicity (1986) (0)
This information is current as Recognition Domains Human TCRs and CARs That Use the Same Comparison of T Cell Activities Mediated by (2017) (0)
Abstract 2980: Single cell RNA sequencing reveals AML immunoediting under pressure from engineered T cell therapy (2018) (0)
342 KRAS G12V T cell receptor-engineered T cells expressing the durability FAS-41BB switch receptor exhibit a potent, persistent, coordinated CD4/CD8 anti-tumor responsein vitroandin vivo (2022) (0)
HIV-speciﬁc CD8 (cid:1) T cells from HIV (cid:1) individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo (2011) (0)
Chapuis Activity and Persist in Post-Transplant Patients T Cells Can Mediate Antileukemic + Transferred WT 1-Reactive CD 8 (2013) (0)
Model of Autochthonous Prostate Cancer Self/Tumor-Specific CD8 T Cells in a Murine Delays but Does Not Prevent Dysfunction of Signaling b Cell-Intrinsic Abrogation of TGF-Ratliff, (2012) (0)
from the Cell Membrane TCR Is Modulated by Target Epitope Distance Antigen Sensitivity of CD22-Specific Chimeric (2011) (0)
Phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T-cell receptor (TCR; FH-TCR TMSLN) in patients with metastatic pancreatic ductal adenocarcinoma (mPDA). (2023) (0)
Abrogation of SHP-1 in tumor-specific effector T cells during adoptive immunotherapy of disseminated leukemia (131.15) (2010) (0)
Cell therapy (SY5-1) Chairpersons: Masaru Taniguchi, Jacques Banchereau (2010) (0)
Does Not Require Cross-Presentation Transgenic Autoantigen Expressed in the Liver T Cells to a + Induction of Tolerance in CD8 (2011) (0)
Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia. (2010) (0)
Molecular Pathways Molecular Pathways : Myeloid Complicity in Cancer (2014) (0)
Abstract 1510: Effects of the lung tumor microenvironment on T cell therapy (2021) (0)
T Cells + the -150 AP-1 Site in Effector CD8 A Transcriptional Block in the IL-2 Promoter at (2011) (0)
Lymphokine-activated Killer Cells Efficacy by Concurrent Administration of Interleukin 2 or Monoclonal Antibody Therapy of Murine Lymphoma : Enhanced Updated (2006) (0)
Developing a clinically relevant ovarian cancer model for use as a platform to test novel immunotherapies that incorporates surgical cytoreduction (2019) (0)
Abstract IA38: Engineered T cell-receptor based therapy of pancreatic ductal adenocarcinoma (2016) (0)
Retinoic acid as an adjuvant to imprint mucosal homing properties to vaccine-induced T cells (39.32) (2009) (0)
Engineering adoptive T cell therapy for efficacy in ovarian cancer (2017) (0)
Retinoic Acid as a Vaccine Adjuvant Enhances CD8 (cid:1) T Cell Response and Mucosal Protection from Viral Challenge (cid:1) † (2011) (0)
Stem cells and cancer immunotherapy (2014) (0)
350. Gene Transfer of Modified Idiotype into Dendritic Cells for Immunotherapy of Non-Hodgkin Lymphomas (2004) (0)
175 A Fas-4–1BB immunomodulatory fusion protein converts a pro-death to a pro-survival signal, enhancing T cell function and efficacy of adoptive cell therapy in murine models of AML and pancreatic cancer (2020) (0)
reprogramming of the primary immune response by T cell receptor antagonism (2004) (0)
Specific Adoptive Therapy of Disseminated Tumors (1987) (0)
CD20-specific T cells mantle cell lymphoma using genetically modified autologous Adoptive immunotherapy for indolent non-Hodgkin lymphoma and (2011) (0)
Specific Adoptive Therapy of Disseminated Tumors (1987) (0)
Antigen Immunotherapy of Tumors Expressing the T Cells or CTL + High-Affinity CD8 Peripheral Tissue Does Not Preclude Recovery of Expression of a Tolerizing Tumor Antigen in (2011) (0)
Priming CD8 (cid:1) T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8 (cid:1) T cells retaining CD28 (2011) (0)
Role of host and donor cells in tumor elimination following adoptive chemoimmunotherapy (acit). Abstr. (1982) (0)
Homeostatic proliferation transiently rescues tolerant CD8+ T cells (41.57) (2009) (0)
Abstract PR08: Enhanced affinity T cell receptor based therapy can surmount immune and physical barriers to treat pancreatic ductal adenocarcinoma (2015) (0)
Monoclonal Antibody Therapy of Murine Lymphoma: Enhanced Efficacy by Concurrent Administration of Interleukin 2 or Lymphokine-activated Killer Cells1 (2006) (0)
668 Lipid-instructed metabolic rewiring unleash the anti-tumor potential of CD8+ T cells (2021) (0)
Abstract PR008: Overcoming PDAC T cell therapy barriers with CD47-targeted costimulatory fusion proteins (2022) (0)
T cell therapy of CMV and HIV infection (1998) (0)
+ ligands together enhances generation of CD8 T-cells with dendritic cells matured using TLR4 and TLR7/8 + (2011) (0)
antigen without requiring knowledge of epitope specificities T cells responding to + and expansion of the full repertoire of CD8 Activation-induced expression of CD137 permits detection, isolation, (2013) (0)
Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells. (2012) (0)
CD8+ T cell responses in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and Molecular modification of idiotypes from B cell lymphomas for expression (2013) (0)
Adoptive therapy of leukemia: efficacy of normal nonimmune cells and cells primarily sensitized in vitro. Abstr. (1980) (0)
the Antigen CTL Immunotherapy of Tumors Expressing T Cells or + Recovery of High-Affinity CD8 Peripheral Tissue Does Not Preclude Expression of a Tolerizing Tumor Antigen in (2001) (0)
results antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial CD20-specific adoptive immunotherapy for lymphoma using a chimeric (2012) (0)
Abstract 1127: Preclinical development of safe and effective T cell receptors specific for mutant KRAS G12D peptide (2023) (0)
Abstract PR12: Early TCRα expression during T cell development for the generation of enhanced-affinity TCRs for TCR gene therapy. (2013) (0)
Downmodulation Lysis and Its Impairment by TCR Triggering Predicts the Magnitude of Target Mathematical Modeling of Chimeric TCR (2010) (0)
Transferred Donor-Derived WT1-Specific CD8+ T-Cell Clones After Hematopoietic Cell Transplantation Mediate Antileukemic Activity and Can Establish Persistent Responses without Toxicity to Normal Tissues in High-Risk Leukemia Patients (2012) (0)
Distinct phenotypic expression of immunogenicity and immuno- sensitivity. Abstr. (1980) (0)
Adoptive therapy with immune T cells. Principles for the treatment of established tumors (1984) (0)
Potential use of cultured T cells and IL-2 in cancer therapy (1989) (0)
twins Treatment of aplastic anemia by bone marrow transplantation in identical (2011) (0)
MicroRNA-150 modulates intracellular Ca2+ levels in naïve CD8+ T cells by targeting TMEM20 (2017) (0)
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation (The Journal of Immunology (2010) 184, (4284-4294)) (2010) (0)
Treatment of refractory acute nonlymphocytic leukemia with a combination of pyrazofurin and cytarabine. (1982) (0)
Abstract IA1: T cells vs. tumor cells: Arming/deploying T cells for a successful battle. (2013) (0)
Reconstitution of Immunity by Adoptive Immunotherapy with T Cells (1999) (0)
Abstract SY31-03: Employing TCRs in engineered T cells to develop therapeutic reagents for effectively targeting malignancies (2015) (0)
Adoptive Transfer of T Cells for Therapy of Disseminated Leukemia: Antigen Specificity And Function of Tumor-Reactive T Cells (2018) (0)
Linoleic acid potentiates CD8+ T cell metabolic fitness and antitumor immunity. (2023) (0)
Nonmyeoloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous t cells in a nonhuman primate model (2000) (0)
The ABCs of T Cell Receptor Gene Therapy (2014) (0)
A process for producing th-independent cytotoxic T zymphozyten (1991) (0)
CD20-speciﬁc adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results (2012) (0)
Tolerant State Rescued Tolerant CD 8 T Cells Are Preprogrammed to Reestablish the (2012) (0)
Abstract A57: Adoptive T cell therapy for ovarian cancer: Application of a surgically relevant model (2018) (0)
Generating therapeutic/protective T-cell responses to tumors and HIV: "More is better, but will it be enough?" (2008) (0)
Abstract PR11: Enhanced in vivo persistence and therapeutic activity of combined transferred polyclonal melanoma-reactive CTL generated in presence of IL-21 and anti-CTLA4. (2013) (0)
Developing Models to Facilitate the Appropriate Selection and Effective Targeting of Candidate Antigens for Specific Cellular Immunotherapy of Prostate Cancer (2006) (0)
Epigenetic memory: tolerant T cells cannot escape their fate (165.40) (2011) (0)
Adoptive immunotherapy of HIV and CMV (1995) (0)
Abstract PR10: Re-engineering immunity to treat pancreas cancer (2015) (0)
Specific adoptive therapy of established murine leukemia with lymphocytes numerically expanded by culture with interleukin 2 (il 2). Abstr. (1981) (0)
Abstract IA18: Building better T cells for targeting and eliminating tumors (2017) (0)
Engineered T cells as reagents to understand and overcome the limitations of naturally- or vaccine-induced T-cell responses (2003) (0)
Top scoring 4E10 and b12 PhIP-Seq 36-mer peptides. (2013) (0)
Antigen-dependent long-term cultured T cells eradicate murine leukemia (1985) (0)
T cell therapy targeting oncogenic antigens in ovarian cancer (2016) (0)
Abstract 2555: Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors (2018) (0)
Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy (2023) (0)
Abstract 3208: Using T cell engineering plus triple checkpoint blockade to enhance the efficacy of adoptive immunotherapy in ovarian cancer (2019) (0)
Characterization of T cell responses specific for a self-antigen expressed in the mouse prostate (40.23) (2009) (0)
P02-05. All-trans retinoic acid during vaccination increases Ag-specific CD8 T cell homing to mucosal sites and improves recall responses to vaginal challenge (2009) (0)
CD8+ T CELLS AS IMMUNOGENIC VACCINE VEHICLES.: 396 (2004) (0)
The Long Road to Develop Adoptive Therapy with T cells that can Effectively Target AML and Other Malignancies (2019) (0)
561 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer (2021) (0)
Monoclonal Antibody Therapy of Murine Lymphoma : Enhanced Efficacy by Concurrent Administration of Interleukin 2 or Lymphokine-activated Killer Cells 1 (2006) (0)
Vaccines Against Virally Induced Cancers - Final Discussion (1994) (0)
Characterization of T cell responses specific for a self-antigen expressed in the mouse prostate (2009) (0)
Adoptive Cellular Therapy for Follicular Lymphoma Using Genetically-Modified Autologous CD20-Specific T Cells. (2007) (0)
Liver Does Not Require Cross-Presentation Transgenic Autoantigen Expressed in the T Cells to a + Induction of Tolerance in CD8 (2007) (0)
Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge (2004) (0)
Supplemental Information miR-150-Mediated Foxo 1 Regulation Programs CD 8 + T Cell Differentiation (2017) (0)
Overcoming obstacles to the generation of T cells for tumor therapy (2006) (0)
Abstract IA02: Engineering T cells to eradicate tumors in the age of synthetic biology (2018) (0)
Pool CellResponse and of the Resulting Memory T AntiviralCells Increases the Size of the Acute T + Receptor Signals to Responding CD 8 Selective Delivery of Augmented IL-2 (2002) (0)
Correction: Mathematical Modeling of Chimeric TCR Triggering Predicts the Magnitude of Target Lysis and Its Impairment by TCR Downmodulation (2010) (0)
Class II-restricted T cells and I-A+ accessory cells are required for the in vitro generation of optimal CTL activity against a class II negative tumor cell line (1985) (0)
Abstract A009: AFNT-111: A novel TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V (2023) (0)
A Membrane-Proximal Region of the Interleukin-2 Receptor (cid:103) c Chain Sufﬁcient for Jak Kinase Activation and Induction of Proliferation in T Cells (1995) (0)
Abstract PO079: Effects of the lung tumor microenvironment on T cell therapy (2021) (0)
244 AFNT-111, a safe and effective TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V mutation (2022) (0)
Abstract 3608: Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer (2022) (0)
Adoptive Immunotherapy of Human Diseases with Antigen-Specific T-Cell Clones (2000) (0)
Interleukin 2 Receptor (1998) (0)
396 CD8+ T CELLS AS IMMUNOGENIC VACCINE VEHICLES. (2004) (0)
Short-Lived Effector T Cells In Vivo Effector Function and Accumulation of Adoptive Immunotherapy by Enhancing the Tumor-Specific T Cells Improves Efficacy of Domain-Containing Phosphatase 1 in Abrogation of Src Homology Region 2 (2012) (0)
Specific Adoptive Therapy of Disseminated Tumors Requirements for Therapeutic Efficacy and Mechanisms by Which T Cells Mediate Tumor Eradication (1987) (0)
Revealed by Deep Sequencing Shaping of Human Germline IgH Repertoires (2012) (0)
74 CD8+ T CELLS AS IMMUNOGENIC VACCINE VEHICLES. (2004) (0)
Molecular modiﬁcation of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4 (cid:1) and CD8 (cid:1) T-cell responses (2005) (0)
H-2 restriction of adoptive immunotherapy of established tumors. Abstr. (1981) (0)
Delivery Of Augmented Il-2 Receptor Signals To Cd8+ T Cells Replaces The Requirement For Helper Function In The Generation Of Primary But Not Secondary Cd8+ T Cell Responses (2007) (0)
SHP-1 regulation of in vivo CD8 T cell responses (35.43) (2009) (0)

This paper list is powered by the following services:

Other Resources About Philip Greenberg

en.wikipedia.org

What Schools Are Affiliated With Philip Greenberg?

Philip Greenberg is affiliated with the following schools:

Philip Greenberg's Academic­Influence.com Rankings

Why Is Philip Greenberg Influential?

Philip Greenberg's Published Works

Published Works

Other Resources About Philip Greenberg

What Schools Are Affiliated With Philip Greenberg?

Philip Greenberg's AcademicInfluence.com Rankings